Bio-Rad Receives Frost & Sullivan's 2005 Product Innovation Award
News Oct 04, 2005
Bio-Rad Laboratories, Inc. has announced that it has received Frost & Sullivan's 2005 ADME/Tox Informatics Product Innovation Award.
Dr. Amarpreet Dhiman, Industry Analyst, Frost & Sullivan Drug Discovery & Diagnostic Technologies Group, UK commented, "As the recipient of the 2005 Frost & Sullivan Product Innovation Award, Bio-Rad Laboratories, Inc. is commended for its success in developing innovative ADME/Tox solutions that bridge the technology gap between downstream and upstream systems."
He continued, "The company's pioneering, all purpose, fully integrated KnowItAll® ADME/Tox Edition suite with ADME/Tox Informatics tools reduces the time and cost involved in drug discovery and development."
"This multi-powerful suite facilitates assessment of the ADME/Tox profiles of potential lead compounds in the initial phases of drug discovery."
"Bio-Rad Laboratories' clear understanding of end user needs coupled with its dedication to address such needs with a technologically advanced product portfolio, therefore makes it a worthy recipient of this award."
Gregory M. Banik, Ph.D., General Manager of Bio-Rad's Informatics Division remarked, "We are tremendously honored to again be the recipient of such a prestigious award."
"By combining partnering technologies with Bio-Rad's award-winning software environment, the KnowItAll system has made a clear mark in the drug discovery community."
"We thank Frost & Sullivan for this recognition. We would also like to extend our gratitude to our development team and the partners with whom we have worked to make this product the success that it is."
Bio-Rad's KnowItAll Informatics System for in silico ADME/Tox is designed to offer a complete suite of tools for the computer-based prediction of a potential drug's ADME/Tox profile, including the one of the largest collections of predictive models, applications to build and validate predictive models, experimental ADME/Tox data, and integrated tools for chemical structure handling, data management, and reporting.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE